289 related articles for article (PubMed ID: 25676724)
1. Innovative Clinical Trials: The LUNG-MAP Study.
Steuer CE; Papadimitrakopoulou V; Herbst RS; Redman MW; Hirsch FR; Mack PC; Ramalingam SS; Gandara DR
Clin Pharmacol Ther; 2015 May; 97(5):488-91. PubMed ID: 25676724
[TBL] [Abstract][Full Text] [Related]
2. Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol.
Redman MW; Papadimitrakopoulou VA; Minichiello K; Hirsch FR; Mack PC; Schwartz LH; Vokes E; Ramalingam S; Leighl N; Bradley J; Miao J; Moon J; Highleyman L; Miwa C; LeBlanc ML; Malik S; Miller VA; Sigal EV; Adam S; Wholley D; Sigman C; Smolich B; Blanke CD; Kelly K; Gandara DR; Herbst RS
Lancet Oncol; 2020 Dec; 21(12):1589-1601. PubMed ID: 33125909
[TBL] [Abstract][Full Text] [Related]
3. Master protocols in lung cancer: experience from Lung Master Protocol.
Lam VK; Papadimitrakopoulou V
Curr Opin Oncol; 2018 Mar; 30(2):92-97. PubMed ID: 29329112
[TBL] [Abstract][Full Text] [Related]
4. Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400.
Herbst RS; Gandara DR; Hirsch FR; Redman MW; LeBlanc M; Mack PC; Schwartz LH; Vokes E; Ramalingam SS; Bradley JD; Sparks D; Zhou Y; Miwa C; Miller VA; Yelensky R; Li Y; Allen JD; Sigal EV; Wholley D; Sigman CC; Blumenthal GM; Malik S; Kelloff GJ; Abrams JS; Blanke CD; Papadimitrakopoulou VA
Clin Cancer Res; 2015 Apr; 21(7):1514-24. PubMed ID: 25680375
[TBL] [Abstract][Full Text] [Related]
5. A decade of advances in treatment for advanced non-small cell lung cancer.
Gettinger S; Lynch T
Clin Chest Med; 2011 Dec; 32(4):839-51. PubMed ID: 22054890
[TBL] [Abstract][Full Text] [Related]
6. Clinical applications of The Cancer Genome Atlas project (TCGA) for squamous cell lung carcinoma.
Devarakonda S; Morgensztern D; Govindan R
Oncology (Williston Park); 2013 Sep; 27(9):899-906. PubMed ID: 24282988
[TBL] [Abstract][Full Text] [Related]
7. Lung-MAP--framework, overview, and design principles.
Ferrarotto R; Redman MW; Gandara DR; Herbst RS; Papadimitrakopoulou VA
Chin Clin Oncol; 2015 Sep; 4(3):36. PubMed ID: 26408303
[TBL] [Abstract][Full Text] [Related]
8. Expression profiling-based subtyping identifies novel non-small cell lung cancer subgroups and implicates putative resistance to pemetrexed therapy.
Hou J; Lambers M; den Hamer B; den Bakker MA; Hoogsteden HC; Grosveld F; Hegmans J; Aerts J; Philipsen S
J Thorac Oncol; 2012 Jan; 7(1):105-14. PubMed ID: 22134068
[TBL] [Abstract][Full Text] [Related]
9. Lung Cancer Genomics in the Era of Accelerated Targeted Drug Development.
Wijesinghe P; Bollig-Fischer A
Adv Exp Med Biol; 2016; 890():1-23. PubMed ID: 26703796
[TBL] [Abstract][Full Text] [Related]
10. Personalized targeted therapy for esophageal squamous cell carcinoma.
Kang X; Chen K; Li Y; Li J; D'Amico TA; Chen X
World J Gastroenterol; 2015 Jul; 21(25):7648-58. PubMed ID: 26167067
[TBL] [Abstract][Full Text] [Related]
11. Emerging drugs for squamous cell lung cancer.
Cheng H; Shcherba M; Kandavelou K; Liang Y; Liu H; Perez-Soler R
Expert Opin Emerg Drugs; 2015 Mar; 20(1):149-60. PubMed ID: 25557559
[TBL] [Abstract][Full Text] [Related]
12. Best practice in the treatment of advanced squamous cell lung cancer.
Ang YL; Tan HL; Soo RA
Ther Adv Respir Dis; 2015 Oct; 9(5):224-35. PubMed ID: 25902866
[TBL] [Abstract][Full Text] [Related]
13. An overview of the design and conduct of the BATTLE trials.
Liu S; Lee JJ
Chin Clin Oncol; 2015 Sep; 4(3):33. PubMed ID: 26408300
[TBL] [Abstract][Full Text] [Related]
14. Pemetrexed in advanced non-small-cell lung cancer.
Fuld AD; Dragnev KH; Rigas JR
Expert Opin Pharmacother; 2010 Jun; 11(8):1387-402. PubMed ID: 20446853
[TBL] [Abstract][Full Text] [Related]
15. Personalised medicine for nonsmall cell lung cancer.
Mascaux C; Tomasini P; Greillier L; Barlesi F
Eur Respir Rev; 2017 Dec; 26(146):. PubMed ID: 29141962
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy for advanced non-small cell lung cancer with a focus on squamous cell carcinoma.
Kuribayashi K; Funaguchi N; Nakano T
J Cancer Res Ther; 2016; 12(2):528-34. PubMed ID: 27461605
[TBL] [Abstract][Full Text] [Related]
17. [Afatinib in patients with squamous cell carcinoma of the lung: current context and the option of oral treatment].
Cobo M; Gutiérrez V; Rodelo L; López O; Ruiz M; Godoy A
Med Clin (Barc); 2016 Apr; 146 Suppl 1():25-9. PubMed ID: 27426245
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 and Lung Cancer: The Era of Precision-ish Medicine?
Borczuk AC; Allen TC
Arch Pathol Lab Med; 2016 Apr; 140(4):351-4. PubMed ID: 26756646
[TBL] [Abstract][Full Text] [Related]
19. Investigational therapies for squamous cell lung cancer: from animal studies to phase II trials.
Shum E; Wang F; Kim S; Perez-Soler R; Cheng H
Expert Opin Investig Drugs; 2017 Apr; 26(4):415-426. PubMed ID: 28277882
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in squamous non-small cell lung cancer: evidence beyond predictive biomarkers.
Genova C; Rijavec E; Grossi F
Expert Rev Anticancer Ther; 2016; 16(1):1-4. PubMed ID: 26567561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]